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Background: Clinical governance has become a core component of health policy and services management in
many countries in recent years. Yet tools for measuring its development are limited. We therefore created the
Clinical Governance Development Index (CGDI), aimed to measure implementation of expressed government policy
in New Zealand.
Methods: We developed a survey which was distributed in 2010 and again in 2012 to senior doctors employed in
public hospitals. Responses to six survey items were weighted and combined to form the CGDI. Final scores for
each of New Zealand’s District Health Boards (DHBs) were calculated to compare performances between them as
well as over time between the two surveys.
Results: New Zealand’s overall performance in developing clinical governance improved between the two studies
from 46% in 2010 to 54% in 2012 with marked differences by DHB. Statistically significant shifts in performance
were evident on all but one CGDI item.
Conclusions: The CGDI is a simple yet effective method which probes aspects of organisational commitment to
clinical governance, respondent participation in organisational design, quality improvement, and teamwork. It could
be adapted for use in other health systems.
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The concept and use of the term ‘clinical governance’
emerged in the late-1990s in the United Kingdom and
has since become central to health policy in a range of
countries [1-3]. Built around an arguably indistinct set
of ideas, clinical governance has been defined in various
ways, making it difficult for both managers and clini-
cians in terms of what they should be aiming for by way
of structures, processes and outcomes [4]. In a general
sense, and following the classic Scally and Donaldson
definition [5], clinical governance involves health care
professionals leading the way in quality improvement
efforts, ensuring practices are evidence-based, and wor-
king to build team-based and systematised service* Correspondence: robin.gauld@otago.ac.nz
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article, unless otherwise stated.delivery processes. Central to clinical governance is the
idea that clinicians are best placed to encourage per-
formance improvement amongst peers [6]. Clinical gov-
ernance may therefore be expressed in terms of health
professionals having two roles: improving the care deliv-
ery system, as well as providing care. Extracting from
this, clinical governance might be seen in both organisa-
tional structures and processes, with an expectation that
improved outcomes will be delivered.
An increasing volume of clinical governance research is
largely focused on the United Kingdom National Health
Service (NHS) and based on case study approaches. For
the most part, the research reveals challenges in develop-
ing leadership models that feature genuine health profes-
sional involvement and often limited opportunities and
management support for clinical governance per se [7-9].
These studies also find difficulties in getting health profes-
sionals to see governance and leadership as a ‘step up’ andd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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delivery. In contrast with many other health services and
management fields, there is a dearth of clinical governance
research aimed at assessing development of structures and
processes or tracking development over time. A 2010 study
presented a method for tracking clinical governance devel-
opment across a disparate range of activities, providing
something of a conceptual framework for evaluation [10].
However, as far as we are aware, this has not been put to
practical use. Others have sought to measure levels of
‘medical engagement’, developing proprietary measures for
this [11,12]. Then there are various tools produced by gov-
ernment agencies for health care providers to use for self-
assessment. Examples include a Western Australian tool
which asks organisational leaders to rate their performance
on eight dimensions of clinical governance development
and provide evidence to support their assessment [13]. The
Irish National Health Executive has taken a similar ap-
proach [14]. Such tools can play an important role in help-
ing providers reflect on their efforts and performance and
highlight for policy makers areas in which additional re-
sources or incentives may be required. However, they are
mostly applied at the organisational level, can be time-
consuming to complete, and may not necessarily capture
the perspectives of front-line health professionals. There is,
therefore, a need for tools that can be used consistently
and over time to compare performances amongst health
care providers and provide an indication of commitment
to clinical governance and its development. Such tools
need to be independently-developed, easy-to-use and in-
corporate the perspectives of front-line professionals.
There is also a need to test and validate tools through prac-
tical application.
With this in mind, in an earlier project we created the
Clinical Governance Development Index (CGDI) designed
for tracking clinical governance development, with a focus
on structures and processes and on measuring implemen-
tation of government policy [15]. The setting was the
government-dominated health system of New Zealand.
This caters to a population of 4.4 million, is around 80%
government-funded from general taxes with the remain-
der from private sources. In 2013, total health expenditure
was 10.3% of GDP. The institutional arrangements that
underpin New Zealand’s health system are not dissimilar
to those of other government-funded jurisdictions [16,17],
although being a small country with a centralised political
system means that change can be rapid [18]. The public
sector dominates hospital care which is provided via 20
District Health Boards. Public hospitals are free of patient
charges; private hospitals offer only elective services with-
out government subsidy, and there are no private emer-
gency services. Primary medical care, by contrast, is
largely privately provided, albeit with considerable govern-
ment subsidies to offset patient co-payments.In early-2009, and drawing heavily on material and
experiences from the NHS – particularly the Leadership
Qualities Framework [19], a government-commissioned
working party made several recommendations for clin-
ical governance development [20]. These included that:
District Health Boards (DHBs) must establish govern-
ance structures ensuring a partnership of clinical and
corporate management; these Boards and their Chief
Executives must enable strong clinical leadership and
decision making and promote this throughout the or-
ganisation; clinical governance must cover the whole
patient journey, with decision making devolved to the
appropriate level; and management must identify clinical
leaders and support their development. The Minister of
Health announced the working party’s recommendations
were to become government policy, with implementa-
tion by DHBs an immediate priority. In 2010, we therefore
sought to measure the extent to which clinical governance
was being implemented by surveying public hospital med-
ical specialists, a group finely attuned to the nuances of
clinical governance and likely to be aware of changes in
leadership and organisational structures. From this pro-
ject, we developed the CGDI. In 2012, we conducted a
follow-up study to investigate progress two years on. This
article outlines the methods for the two surveys, results,
derivation of the index and implications for utilising it.
Methods
For the 2010 study, we developed a fixed-response 11-
item survey, with an additional eight background ques-
tions and comments box. Survey items related directly to
the key policy statements in the clinical governance work-
ing party’s report [20]. Thus, respondents were asked to
rate the extent of familiarity with clinical governance con-
cepts and policy. In a series of related questions, they
rated the extent to which they perceived their employer
organisation was working to develop and support clinical
governance and partner with clinicians, from the level of
the board and senior management through to front-line
services. The survey was peer-reviewed through the devel-
opment process by six researchers and medical profes-
sionals, along with the 10 members of the National
Executive of the Association of Salaried Medical Special-
ists (ASMS), the national public hospital specialists union.
A draft was then piloted among two groups of hospital
specialists (22 in total) with further adjustments following
feedback. Through the scrutiny of these groups, the survey
questions and design fulfilled the standards of both ‘face’
and ‘construct’ validity [21].
All New Zealand public hospital specialists are salaried
employees of one of the 20 District Health Boards they
work for. Over 90% of these specialists are members of
the ASMS. The self-completed survey was distributed in
paper form by ASMS to its 3402 members in June 2010,
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based survey sought participation with an email invite to
those who had not responded to the paper version, with
two subsequent email reminders. Data from paper sur-
veys were converted into electronic form and merged
with data from the web survey, with no significant differ-
ences in response patterns found.
The CGDI was formed through combining responses
from seven survey items representing related aspects of
processes involved in developing clinical governance. The
index demonstrated good internal consistency, with a
Cronbach’s alpha of 0.80.
The 2012 survey was modified, and its validity enhanced,
in a consultative process that involved over 200 health pro-
fessionals employed by DHBs, government policy makers
and DHB managers. The 2012 study had a broader scope
in that it included all health professionals. Thus, a total of
41030 professionals, including doctors, nurses, midwives
and allied service providers, were invited by their DHB hu-
man resources department to participate in an online sur-
vey. Inclusion criteria were that invitees must be registered
health professionals, in on-going full- or part-time employ-
ment with their DHB, and with an official DHB email ad-
dress (in theory, any such DHB employee has one). Invites,
containing a link to the survey website, were sent to em-
ployee email addresses. Three follow-up emails were sent
to employees at weekly intervals. A national communica-
tions campaign ensured that all 19 participating DHBs dis-
tributed standard instructions (Canterbury DHB did not
participate due to the earthquake recovery process).
The 2012 survey did not include one of the survey items
which contributed to the CGDI in the 2010 survey, andTable 1 Survey items from the 2010 and 2012 versions of the
Item Scoring CGDI item from 2010 survey
1 Yes = 1, No = 0 To your knowledge, has your D
established a governance struc
partnership between clinicians
2 A great extent = 2, Some extent = 1,
No extent = 0
To what extent are clinicians in
involved in a partnership with m
shared decision making, respon
accountability?
3 A great extent = 2, Some extent = 1,
No extent = 0
To what extent are clinicians in
involved as full active participan
governance decision making pr
4 A great extent = 2, Some extent = 1,
No extent = 0
To what extent do you believe
safety is a goal of every clinical
DHB hospital?
5 A great extent = 2, Some extent = 1,
No extent = 0
To what extent do you believe
safety is a goal of every admini
your DHB hospital?
6 A great extent = 2, Some extent = 1,
No extent = 0
To what extent has your DHB s
responsibility for clinical service
in your clinical areas?
7 A great extent = 2, Some extent = 1,
No extent = 0
To what extent has your DHB le
to identify clinical leaders?minor changes in wording were made to some items. This
was to improve their relevance to an inter-professional
audience and reduce any perceived biases associated with
the ASMS involvement in the earlier survey. An amended
CGDI was therefore created for the 2012 survey using the
remaining common six CGDI survey items. Table 1 lists
the items from each version of the CGDI, as well as how
the items are scored. An individual’s CGDI was arrived at
by summing their scores for each item. These raw scores
were converted to percentages for final presentation.
‘Don’t know’ responses were treated as missing values. A
CGDI was only calculated for individuals with no missing
values. To obtain the overall CGDI for a DHB, the mean
CGDI of all individuals from that DHB was calculated.
For the purposes of analyses for this article, only data from
medical specialists in the 2012 survey were included in
the comparisons (since the 2010 survey only included
these professionals). All analyses were performed using
the R statistical system version 2.12 [22].
The study protocol and survey tool were reviewed, in-
cluding for ethical considerations, and approved by the
National Executive of the Association of Salaried Medical
Specialists, National Executive of the National Health
Board, Board and executive team of the Health Quality
and Safety Commission, and CEO and leadership teams of
the participating DHBs.
Results
The 2010 survey achieved a response rate of 52%; some
32% of senior medical officers responded to the 2012
survey. Response rates differed by DHB, as may be ex-
pected of a large multi-regional study of this nature. InCGDI
CGDI item from 2012 survey
HB board
ture that ensures a
and management?
To your knowledge, has your DHB established
governance structures that ensure a partnership




To what extent are health professionals in your
DHB involved in a partnership with management





To what extent are health professionals in your
DHB involved as full active participants in the
design of organisational processes?
that quality and
initiative in your
To what extent do you believe that quality and




To what extent do you believe that quality and
safety is a goal of every clinical resourcing or
support initiative in your DHB?
ought to give you
decision making
To what extent has your DHB sought to give
responsibility to your team for clinical service
decision making in your clinical areas?
adership sought Not included.
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tween individual DHBs (mean = 51%, SD = 7%); in 2012,
the range was 10% to 73% (mean = 39%, SD = 16%). Re-
spondent characteristics in both surveys were compared
with DHB health workforce data and found to be close
to those of all potential respondents.
After applying the various exclusions outlined in the
previous section, 1487 respondents from the 2010 survey
and 1313 from the 2012 survey were included in the
analysis. Of these, 944 (63%) and 856 (65%) had
complete data and could have a CGDI score computed.
The results are presented in Table 2. As represented in
the increase from 46 to 54% in the mean score, the re-
sults show considerable progress across the DHBs in the
two years between the surveys. Several DHBs demon-
strated substantial improvement with, in one case, an in-
crease from 44 to 64% in the index score. One DHB’s
score decreased. It needs to be acknowledged that this is
one of the smallest DHBs and a small number of respon-
dents to the 2012 survey meant the score was highly
sensitive to small changes in response patterns. There
was evidence of substantial variation in the CGDI scores
of different DHBs in both the 2010 and 2012 surveys. In
2010, the range was 38–55%; in 2012, the level of vari-
ation broadened to 36–65%.Table 2 Comparison of CGDI scores for the 2010 and
2012 surveys
DHB 2010 survey 2012 survey Change
South Canterbury 44% 64% 20
Whanganui 40% 58% 18
Hawke’s Bay 44% 61% 17
Taranaki 47% 64% 17
Counties Manukau 52% 65% 13
Nelson Marlborough 41% 53% 12
Waitemata 47% 58% 11
Wairarapa 39% 49% 10
Northland 46% 55% 9
Lakes 49% 58% 9
Waikato 46% 52% 5
MidCentral 43% 47% 4
Auckland 49% 53% 4
Hutt Valley 49% 52% 3
Bay of Plenty 38% 41% 2
Capital and Coast 54% 57% 2
Tairawhiti 55% 56% 1
Southern 42% 42% 0
West Coast 41% 36% −5
Mean 46% 54% 8
Note that the numbers have been rounded, which may make the difference
not appear to equal the difference between the two survey scores.Table 3 contains the mean of the mean scores for re-
spondents across DHBs for 2010 and 2012. The fourth
column in the table lists the change in the means over
the two surveys for each CGDI item, showing significant
improvement in all but item 3, with the most marked
improvement in items 5 and 6.
Discussion
With our 2010 study, we developed the CGDI and, fol-
lowing feedback from New Zealand health care profes-
sionals, their employers and policy makers, modified the
original survey tool for our 2012 follow-up. In this re-
gard, and given the input of a wide range of individuals
into the 2012 instrument design, we believe we have en-
hanced its validity.
We argue that the CGDI offers a straightforward and
efficient means of measuring the extent to which a
health care organisation is working to facilitate clinical
governance. There are various reasons for this, including
that the CGDI draws its measures from the perspective
of health professionals. While there is an obligation on
the part of professionals to take up opportunities to get
involved in clinical governance activities, robust clinical
governance demands managerial facilitation. Thus, pro-
fessionals should be able to gauge the extent to which
managerial and organisational activities are focused on
building clinical governance, as well as the level of em-
phasis on clinical governance components such as qual-
ity and safety improvement. Importantly, the CGDI
mixes items that probe both management and clinician
activities; in our study, these items sought to measure
the implementation of stated policy. The CGDI can also
be used as a yardstick for assessing performances on clin-
ical governance over time as well as between organisations
which can be useful as a stimulant for improvement. Fi-
nally, in contrast with other tools for measuring clinical
governance [10], the CGDI is focused on a defined set of
important goals and processes that includes relationships
between managers and health professionals, involvement
in organisational design, and quality improvement which
are central to the original Scally and Donaldson definition
of clinical governance. This involved developing:
… a system through which health organisations are
accountable for continuously improving the quality of
their services and safeguarding high standards of care
by creating an environment in which excellence in
clinical care will flourish [5].
Our use of the CGDI suggests positive progress in clinical
governance development across New Zealand’s DHBs, at
least from the perspective of senior doctors. In this regard,
it indicates traction with the policy implementation process,
with some DHBs making considerably more progress than
Table 3 Change in mean DHB ratings (i.e. mean of the DHB means) for each of the CGDI items across the two surveys,
with higher scores indicating more positive mean responses
2010 2012
Survey item (scoring range) DHB Mean (SD) DHB Mean (SD) Change 95% CI for Change p =
To your knowledge, has your DHB established governance structures
that ensure a partnership between health professionals and
management? (0–1)
0.64 (0.12) 0.71 (0.12) +0.08 +0.03 – +0.12 0.0040*
To what extent are health professionals in your DHB involved in a
partnership with management with shared decision making,
responsibility and accountability? (0–2)
0.87 (0.15) 1.04 (0.16) +0.17 +0.07 – +0.27 0.0023*
To what extent are health professionals in your DHB involved as full
active participants in the design of organisational processes? (0–2)
0.88 (0.14) 0.93 (0.15) +0.05 −0.04 – +0.14 0.2533
To what extent do you believe that quality and safety is a goal of every
clinical initiative in your DHB? (0–2)
1.12 (0.09) 1.28 (0.14) +0.16 +0.09 – +0.23 0.0001*
To what extent do you believe that quality and safety is a goal of every
clinical resourcing or support initiative in your DHB? (0–2)
0.83 (0.09) 1.08 (0.14) +0.25 +0.17 – +0.33 0.0000*
To what extent has your DHB sought to give responsibility to your
team for clinical service decision making in your clinical areas? (0–2)
0.74 (0.10) 1.00 (0.19) +0.26 +0.16 – +0.36 0.0000*
Three DHBs have been removed because of low numbers (fewer than 10) or not taking part in both surveys, leaving 924 and 849 respondents for the 2010 and
2012 surveys respectively.
SD = Standard Deviation.
95% CI = 95% Confidence Interval.
* = Statistically significant at the p = 0.05 level.
p-values obtained using Student’s t-test for paired data, with the DHBs across the two surveys as the pairs.
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questions of how they achieved this, and why others did
not. In some cases, DHBs obviously had better scores in
the initial 2010 survey so started from a much stronger
position. In other cases, the DHB may have had a more
concerted strategy for implementing clinical governance in
place, in turn leading to survey respondent perceptions of
better performance. In 2012, we conducted in-depth case
studies of each DHB in parallel with the survey study
through a mix of DHB self-reviews, document analysis and
key informant interviews. Our aim was to analyse each
DHB’s clinical governance strategy, the structures to facili-
tate clinical governance and leadership that had been im-
plemented, and to learn about the challenges the DHB
faced in the clinical governance development process [23].
As a general rule of thumb, the 2012 CGDI scores reported
in this article matched closely the levels of development in
each DHB and interviewee perceptions of performance.
Thus, perhaps the most compelling explanation for the
CGDI changes lies in where, in reality, on the trajectory of
change the DHB was: some were clearly further along in
their developmental journey, or had made considerably
more progress in a short time than others, or had started to
see the payoff from an early commitment to clinical gov-
ernance. In some DHBs, it may be that there was simply
more acceptance and knowledge of key concepts and ter-
minology. In 2010 and 2012, we asked the question: ‘Clin-
ical leadership is described as “…a new obligation to step
up, work with other leaders, both clinical and managerial,
and change the system where it would benefit patients”.
How familiar are you with this concept?’ Some 51% ofresponding specialists expressed familiarity in 2010, [15]
compared with 58% in 2012 [23]. Beyond the individual
DHB setting, there had been no substantial changes to na-
tional policy settings between 2010 and 2012 so explana-
tions for the CGDI changes would appear to lie in activities
at the individual DHB level rather than the broader health
system level, in contrast with explanations often provided
in other policy studies [24,25].
While there was an overall CGDI score increase be-
tween 2010 and 2012, analysis of changes in the scores
for individual index items is revealing with 5 of the 6
showing marked improvement. Survey respondents are
obviously seeing development of partnership governance
and decision making structures, increased attention to
quality and safety in terms of both organisational resour-
cing as well as in care delivery, and increased clinical
team responsibility for decision making. The item prob-
ing respondent participation in organisational design
processes, on which improvement was not shown to be
statistically significant, indicates that this is an area the
DHBs perhaps need to focus more upon.
While our follow-up study does imply positive improve-
ment, it also suggests on-going effort is required if New
Zealand is to develop robust clinical governance across all
DHBs. Some are obviously making more progress than
others; some have made limited, if any, progress. Indeed, it
might be suggested that the 2012 performance, as a whole,
remains mediocre at 54% with the top scoring DHB
achieving only 64%. The individual CGDI items, which link
into both New Zealand government policy as well as litera-
ture on health system improvement, collectively provide
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the introduction, and probed in these survey items, studies
variously show that a strong focus on clinical leadership,
quality and safety and teamwork can improve health sys-
tem performance and patient outcomes while reducing
costs [26-28]. Thus, the DHBs would do well to intensify
their efforts in these areas.
Yet New Zealand, with its perhaps middling performance
on clinical governance, is not alone. Elsewhere, studies
show the struggle continues with attempting to bridge the
managerial-clinical divide and build entities with strong
clinical leadership focused on quality and safety [2,29,30].
The reasons for this may, again, be due to leadership cap-
acity, as well as the context-dependent nature of any man-
agement and organisational development project which
means it is difficult to simply transplant a well-functioning
model of clinical governance from one organisation into
another. Organisational re-development also takes consid-
erable time, meaning higher CGDI scores could be envis-
aged as the developmental and implementation processes
mature. The reason for New Zealand’s middling perform-
ance may also be due to health professionals, particularly
senior doctors, having enough time in their already busy
schedules to dedicate to clinical governance and leadership
activities. They may also have limited interest in the ‘higher
calling’ of leadership, especially if they have received lim-
ited training in the field and perhaps see this as a non-core
duty. While our survey study did not probe this area, there
is a strong argument that leadership training should feature
early in health professional education and be promoted
more widely [31-33]. This was a common theme in site
visits and interviews with health professionals which we
conducted in association with the 2012 survey, reported on
elsewhere [23].
The research reported in this article has some limita-
tions. First, the self-completed survey method relies on
individual perceptions and has associated biases. How-
ever, response patterns were consistent across returned
surveys from the different districts in both the 2010 and
2012 studies. Second, response rates above 52 and 32%
for the two surveys respectively would have been desir-
able, but these rates were around the level obtained in
comparable studies and there is a growing recognition
that higher response rates are increasingly difficult to at-
tain [34]. A review of research in a related field con-
cluded that 55% is considered to be ‘one of the best
response rates’ [35]. The low response rates were com-
pounded by missing responses in the CGDI items,
meaning that the 2012 results were ultimately based on
responses from 21% of senior doctors. Very importantly,
as noted, our respondent characteristics were similar to
those of the broader health workforce suggesting that re-
sponse bias would be limited. While we do not know
whether non-responders had different perspectives fromthose who did respond, feedback received at presentations
to New Zealand medical specialist conferences gives us no
reason to believe a higher participation rate would have
substantially changed the findings. That said, it is possible
that the non-responders featured a larger proportion of
professionals who felt un-engaged. If so, then the results in
our study could indicate a higher level of clinical govern-
ance development than the reality. Third, our survey in-
cluded only medical specialists. A follow-up study will
permit tracking progress with clinical governance develop-
ment from the perspective of the full range of New Zealand
health professionals, given their participation in the 2012
survey. Fourth, the simple survey method means we were
unable to probe why some DHBs performed better than
others, or why some had achieved substantial changes be-
tween the two surveys. Answers to these questions might
be explored through in-depth research methods such as re-
views of policy documents and interviews with key infor-
mants. Finally, it would be useful to look at whether CGDI
performances are predictive of performances on other mea-
sures in areas such as finance, organisational efficiency and
patient safety.
Conclusions
The CGDI and its application in the New Zealand
context provides a baseline for further research. This
might involve additional work on validating the ques-
tionnaire and CGDI, and adapting it for use in other
health systems. It could also continue to be used for
monitoring progress with clinical governance develop-
ment in New Zealand. Of course, following from the
above, a key question that arises is whether the New
Zealand case is substantially different from that of
other countries and, in turn, how applicable the CGDI
is for use elsewhere. As noted in the introduction,
New Zealand’s clinical governance policy drew heavily
from the United Kingdom’s NHS; New Zealand’s health
system is not dissimilar from other government-funded
systems. Where New Zealand’s experience does differ
from some countries that have pursued clinical govern-
ance could be in the relatively directive nature of policy
emanating from central government, and in its smallness.
Indeed, in a country such as North America, clinical gov-
ernance is mostly an individual hospital-specific policy
[36,37]. Yet this does not mean the CGDI could not be
used in quite different health systems. In our study, we
measured both local and national progress with clinical
governance development through a lens predominantly
that of specialists employed in individual hospitals. This
implies that the index could be used in individual hospitals
elsewhere, within a differently-structured health system,
or to measure and compare performance more broadly
in a system with characteristics that are closer to New
Zealand’s.
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